The beneficial role of SIRT1 activator on chemo- and radiosensitization of breast cancer cells in response to IL-6

Immunomodulatory Factors Control the Fate of Melanoma Tumor Initiating Cells

(2016) Alessandra Tuccitto et al.   STEM CELLS

The Role and Application of Sirtuins and mTOR Signaling in the Control of Ovarian Functions

(2016) Alexander Sirotkin   Cells

BRCA1 inhibits AR–mediated proliferation of breast cancer cells through the activation of SIRT1

(2016) Wenwen Zhang et al.   Scientific Reports

The Sirt1 activator SRT1720 attenuates angiotensin II-induced atherosclerosis in apoE−/− mice through inhibiting vascular inflammatory response

(2015) Yi xi Chen et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

SIRT1-Activating Compounds (STAC) Negatively Regulate Pancreatic Cancer Cell Growth and Viability Through a SIRT1 Lysosomal-Dependent Pathway

(2015) C. C. S. Chini et al.   CLINICAL CANCER RESEARCH

Endoplasmic Reticulum (ER) Stress Induces Sirtuin 1 (SIRT1) Expression via the PI3K-Akt-GSK3β Signaling Pathway and Promotes Hepatocellular Injury

(2015) Tomoaki Koga et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The Role of Cytokines in Breast Cancer Development and Progression

(2015) Marcela Esquivel-Velázquez et al.   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

Regulation of Akt Signaling by Sirtuins

(2014) Vinodkumar B. Pillai et al.   CIRCULATION RESEARCH

Correlation and prognostic value of SIRT1 and Notch1 signaling in breast cancer

(2014) Yu-Wen Cao et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

SIRT1 Inactivation Evokes Antitumor Activities in NSCLC through the Tumor Suppressor p27

(2014) Lijia Zhu et al.   MOLECULAR CANCER RESEARCH

High levels of SIRT1 expression enhance tumorigenesis and associate with a poor prognosis of colorectal carcinoma patients

(2014) Xiaojing Chen et al.   Scientific Reports

The role of intratumoral and systemic IL-6 in breast cancer

(2013) Christine Dethlefsen et al.   BREAST CANCER RESEARCH AND TREATMENT

Radiosensitization of prostate cancer cells by the dual PI3K/mTOR inhibitor BEZ235 under normoxic and hypoxic conditions

(2013) Vincent A. Potiron et al.   RADIOTHERAPY AND ONCOLOGY

Interleukin-6 signaling pathway in targeted therapy for cancer

(2012) Yuqi Guo et al.   CANCER TREATMENT REVIEWS

Higher importance of interleukin 6 than classic tumor markers (carcinoembryonic antigen and squamous cell cancer antigen) in the diagnosis of esophageal cancer patients

(2011) M. Łukaszewicz-Zając et al.   DISEASES OF THE ESOPHAGUS

Breast cancer stem cells, cytokine networks, and the tumor microenvironment

(2011) Hasan Korkaya et al.   JOURNAL OF CLINICAL INVESTIGATION

Levels of p27 Sensitize to Dual PI3K/mTOR Inhibition

(2011) M. Lee et al.   MOLECULAR CANCER THERAPEUTICS

Significance of Interleukin-6 Signaling in the Resistance of Pharyngeal Cancer to Irradiation and the Epidermal Growth Factor Receptor Inhibitor

(2010) Chih-Cheng Chen et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Clinical significances of preoperative serum interleukin-6 and C-reactive protein level in operable gastric cancer

(2009) Do-Kyong Kim et al.   BMC CANCER

Interleukin-6 trans-signalling differentially regulates proliferation, migration, adhesion and maspin expression in human prostate cancer cells

(2009) Frédéric R Santer et al.   ENDOCRINE-RELATED CANCER

STAT3 inhibition of gluconeogenesis is downregulated by SirT1

(2009) Yongzhan Nie et al.   NATURE CELL BIOLOGY

NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations

(2008) V. Serra et al.   CANCER RESEARCH

mTOR-Raptor Binds and Activates SGK1 to Regulate p27 Phosphorylation

(2008) Feng Hong et al.   MOLECULAR CELL

Involvement of CD44, a molecule with a thousand faces, in cancer dissemination

(2008) David Naor et al.   SEMINARS IN CANCER BIOLOGY